Endometriosis Treatment Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 5.30 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Endometriosis Treatment Market Analysis
The Endometriosis Treatment Market is expected to register a CAGR of 5.3% over the forecast period, 2022-2027.
COVID-19 pandemic had a substantial impact on patients with chronic disease conditions like endometriosis. The strict lockdowns and government regulations intended to slow down the spread of COVID-19 resulted in a decrease in demand for products across all segments. In wake of the COVID-19 outbreak, women with endometriosis are particularly exposed to the risk of post-traumatic stress disorder during the SARS-CoV-2 pandemic, especially if they are older or have higher levels of anxiety.
As per the articles published in October 2021 titled 'Effects of the SARS-CoV-2 pandemic on women affected by endometriosis in the National Library of Medicine, 68.8% were quite extremely worried about not being able to access gynecologic care during this period, thus, the COVID-19 had a significant impact on the endometriosis treatment market.
According to World Health Organization, in 2021 endometriosis affects roughly 10% (190 million) of reproductive-age women and girls globally. Further, the rise in the prevalence of endometriosis, growing awareness of the disease, and growing need for early diagnosis are among the major factors driving the growth of the studied market. Such factors are likely to boost the adoption of the endometriosis treatment market, thereby contributing to the studied market growth.
In addition, growing awareness and research and development funding by major players in the market are positively affecting the growth of the studied market. For instance, in February 2021 the DBT Wellcome India Alliance is supporting a major national research project 'Endometriosis Clinical and Genetic Research in India (ECGRI)' that aims to broaden understanding of the clinical phenotypes and genetic risks associated with endometriosis. Additionally, in February 2021, the European Union is supporting a major international research and innovation project that aims to improve the treatment and quality of life of those with endometriosis.
Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period. However, the high cost of endometriosis treatment is likely to impede the market growth.
Endometriosis Treatment Market Trends
This section covers the major market trends shaping the Endometriosis Treatment Market according to our research experts:
Pain Medication segment is Expected to Witness Significant Growth Over the Forecast Period
Endometriosis is associated with painful symptoms such as chronic pelvic pain, dysmenorrhea and dyspareunia, infertility, and psychological suffering among others. The medical treatment of endometriosis can deal with painful symptoms of the disease and, consequently, reduce the negative impact on quality of life and mental health. The medication has a high safety profile, good tolerance, few side effects, and reasonable costs. Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most common pain medications for endometriosis. Over-the-counter NSAIDs include aspirin, ibuprofen, and naproxen. NSAIDs block the development of prostaglandins, a type of biological compound produced in the body. Prostaglandins cause swelling, pain, and inflammation that many women with endometriosis experience during their periods.
Furthermore, a continuous collaboration by major players in the market is positively affecting the growth of the segment. For instance, in February 2022 ObsEva SA announced a strategic licensing agreement with Theramex to support the commercialization and market introduction of linzagolix across global markets outside of the United States, Canada, and Asia. Linzagolix is in development as a potential treatment for endometriosis-associated pain, and ObsEva recently announced positive topline results for its first Phase 3 trial (EDELWEISS 3) in this indication.
North America is Expected to Dominate the Endometriosis Treatment Market
North America is expected to dominate the market owing to factors such as the easy availability of technologically advanced products, the rising prevalence of endometriosis, and awareness about health in this region. For instance, according to the data published by the Office on Women's Health in 2021, endometriosis affects more than 11% of women between ages 15 and 44 and is common among women in their 30s and 40s in the United States.
Key product launches, high concentration of market players, or manufacturer's presence in the United States are some of the factors driving the growth of the endometriosis Treatment Market in the country. For instance, in August 2022, Myovant Sciences and Pfizer announce United States Food and Drug Administration (FDA) approved MYFEMBREE for the management of moderate to severe pain associated with endometriosis in pre-menopausal women. The drug offers a once-daily effective treatment option for the management of moderate to severe endometriosis pain, with a treatment duration of up to 24 months. Therefore, owing to the above-mentioned factors North America Endometriosis Treatment Market is expected to dominate and register higher growth over the forecast period.
Endometriosis Treatment Industry Overview
The Endometriosis Treatment Market is fragmented in nature due to the presence of several companies operating globally as well as regionally. Most of the big companies are focusing on research and development to bring innovative products to the market. Some of the major players include Bayer AG, Lannett, Pfizer Inc., Sun Pharmaceutical Industries Limited, Cipla Limited, Teva Pharmaceutical Industries Ltd, Zydus Healthcare Limited, TerSera Therapeutics USA, Tolmar Pharmaceuticals, Inc., AbbVie Inc., and Sandoz AG.
Endometriosis Treatment Market Leaders
Bayer AG
Pfizer Inc.
AbbVie Inc.
Lannett
Teva Pharmaceutical Industries
*Disclaimer: Major Players sorted in no particular order
Endometriosis Treatment Market News
- In February 2022 ObsEva SA announced a strategic licensing agreement with Theramex to support the commercialization and market introduction of linzagolix across global markets outside of the United States, Canada, and Asia. Linzagolix is in development as a potential treatment for endometriosis-associated pain, and ObsEva recently announced positive topline results for its first Phase 3 trial (EDELWEISS 3) in this indication.
- In January 2022, ObsEva SA announced positive topline results from the Phase 3 EDELWEISS 3 trial of linzagolix, an oral GnRH antagonist, in women with moderate-to-severe endometriosis-associated pain (EAP).
Endometriosis Treatment Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Driver
4.2.1 Rise in the Prevalence of Endometriosis
4.2.2 Growing Awareness of the Disease and Growing Need of Early Diagnosis
4.3 Market Restraints
4.3.1 High Cost Associated With The Treatment
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Type
5.1.1 Superficial Peritoneal Endometriosis
5.1.2 Endometriomas
5.1.3 Deeply Infiltrating Endometriosis
5.1.4 Other Types
5.2 By Treatment Type
5.2.1 Pain Medication
5.2.2 Hormone Therapy
5.3 By End User
5.3.1 Hospitals
5.3.2 Specialty Clinics
5.3.3 Other End Users
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Bayer AG
6.1.2 Lannett
6.1.3 Pfizer Inc.
6.1.4 Sun Pharmaceutical Industries Limited
6.1.5 Cipla Limited
6.1.6 Teva Pharmaceutical Industries Lt
6.1.7 Zydus Healthcare Limited
6.1.8 TerSera Therapeutics USA
6.1.9 Tolmar Pharmaceuticals, Inc.
6.1.10 AbbVie Inc.
6.1.11 Sandoz AG
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Endometriosis Treatment Industry Segmentation
As per the scope of the report, endometriosis is a disease where tissue similar to the lining of the uterus grows outside the uterus, causing pain and/or infertility. The Endometriosis Treatment Market is segmented by Type (Superficial Peritoneal Endometriosis, Endometriomas, Deeply Infiltrating Endometriosis, and Other Types), By Treatment Type (Pain Medication and Hormone Therapy), End User (Hospitals, Specialty Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.
| By Type | |
| Superficial Peritoneal Endometriosis | |
| Endometriomas | |
| Deeply Infiltrating Endometriosis | |
| Other Types |
| By Treatment Type | |
| Pain Medication | |
| Hormone Therapy |
| By End User | |
| Hospitals | |
| Specialty Clinics | |
| Other End Users |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Endometriosis Treatment Market Research FAQs
What is the current Global Endometriosis Treatment Market size?
The Global Endometriosis Treatment Market is projected to register a CAGR of 5.30% during the forecast period (2024-2029)
Who are the key players in Global Endometriosis Treatment Market?
Bayer AG, Pfizer Inc., AbbVie Inc. , Lannett and Teva Pharmaceutical Industries are the major companies operating in the Global Endometriosis Treatment Market.
Which is the fastest growing region in Global Endometriosis Treatment Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Endometriosis Treatment Market?
In 2024, the North America accounts for the largest market share in Global Endometriosis Treatment Market.
What years does this Global Endometriosis Treatment Market cover?
The report covers the Global Endometriosis Treatment Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Endometriosis Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Global Endometriosis Treatment Industry Report
Statistics for the 2024 Global Endometriosis Treatment market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Global Endometriosis Treatment analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
